Although only 10–20% of ovarian cancers have germline BRCA1/2 mutations [2,38,39,40], up to 51% of high-grade serous OC tumor cells contain either a genetic or epigenetic inactivation of BRCA1/2 [16], making both treatment combinations an attractive strategy for recurrent BRCA1/2 mutant OC. The gene discussed is BRCA1; the disease is ovarian cancer.